Christopher Rota

Christopher Rota's work experience includes various roles in the field of biomedical research. Christopher started their career as an undergraduate researcher at the University of North Carolina at Chapel Hill, where they conducted independent research on DNA repair. This project served as the basis of their senior honors thesis and was presented at a conference.

After completing their undergraduate studies in 2014, Christopher joined the National Cancer Institute (NCI) as a CRTA Post-Baccalaureate Research Fellow. In this role, they focused on developing novel immunotherapies for pediatric brain tumors using chimeric antigen receptors.

In 2016, Christopher enrolled in Harvard Medical School as a PhD candidate in Biological and Biomedical Sciences. Their dissertation work was conducted in the lab of Dr. Rosalind Segal at the Dana-Farber Cancer Institute. Their research projects at Harvard aimed to advance their training as a cancer biologist and focused on the intersection of normal developmental neurobiology and pediatric brain cancer biology.

Most recently, Christopher joined Cerba Research in 2022 as a Scientist in Flow Cytometry.

Christopher Rota pursued their education in a disciplined and focused manner. Christopher began their academic journey in 2010 at the University of North Carolina at Chapel Hill, where they obtained a Bachelor of Science (B.S.) degree in Biology/Biological Sciences, General in 2014. After completing their undergraduate studies, Christopher decided to further their knowledge and expertise in Biological and Biomedical Sciences. As a result, they enrolled in Harvard Medical School in 2016 to pursue a Doctor of Philosophy (PhD) degree. Christopher successfully completed their PhD program at Harvard in 2022, emphasizing their dedication to their chosen field of study.